

pirtobrutinib (JAYPIRCA)

Diagnoses Considered for Coverage:

- Mantle cell lymphoma
- Chronic lymphocytic leukemia (CLL) or Small lymphocytic lymphoma (SLL)

Coverage Criteria:

For mantle cell lymphoma:

1. Disease is relapsed or refractory, **and**
2. Patient has received at least two prior lines of systemic therapy, **and**
3. Being used as single agent, **and**
4. Dose does not exceed 200 mg per day.

For chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL):

1. Being used as a single agent, **and**
2. Dose not to exceed 200 mg per day, **and**
3. One of the following:
 - a. Patient has resistance or intolerance to prior covalent Bruton Kinase inhibitor (e.g., ibrutinib (Imbruvica), acalabrutinib (Calquence) or zanubrutinib (Brukinsa)) **or**
 - b. Patient has relapsed or refractory disease following prior treatment with a Bruton tyrosine kinase inhibitor and a BCL 2 inhibitor (e.g., venetoclax (Venclexta), bosutinib (Bosulif)), **or**
 - c. **Being used for Richter's transformation to diffuse large B-cell lymphoma (DLBCL), and either of the following:**
 - I. Patient has del(17p)/TP53 mutation, **or**
 - II. Patient is chemotherapy refractory or unable to receive chemoimmunotherapy

Coverage Duration: one year

References:

1. **Prescribing Information. Jaypirca. Eli Lilly. December 2023.**

Effective Date: 2/28/2024